Daftar Pustaka

Abbasi, F., Chu, J. W., Lamendola, C., McLaughlin, T., Hayden, J., Reaven, G. M.,et al. (2004). Discrimination between obesity and insulin resistance in the relationship with adiponectin. *Diabetes*, *53*(3), 585–590.

American Diabetes Association. (2010). Diagnosis and classification of diabetes melitus. *Diabetes care*, 33 Suppl 1(Suppl 1), S62–S69.

American Diabetes Association. (2015). Standards of medical care in diabetes-2015 abridged for primary care providers. *Clin diabetes : a publication of the American Diabetes Association*, *33*(2), 97–111.

American Diabetes Association. (2020). Classification and diagnosis of diabetes: Standards of medical care in diabetes—2021. *Diabetes Care*, *44*(Supplement 1), S15–S33.

Amemiya-Kudo, M., Shimano, H., Hasty, A. H., Yahagi, N., Yoshikawa, T., Matsuzaka, T., et al. (2002). Transcriptional activities of nuclear SREBP-1a, -1c, and -2 to different target promoters of lipogenic and cholesterogenic genes. *J Lipid Res*, *43*(8), 1220–1235.

Arafat, A. M., Weickert, M. O., Adamidou, A., Otto, B., Perschel, F. H., Spranger, J., et al. (2013). The impact of insulin-independent, glucagon-induced suppression of total ghrelin on satiety in obesity and type 1 diabetes mellitus. *J. Clin. Endocr.*, *98*(10), 4133–4142.

Arkan, M. C., Hevener, A. L., Greten, F. R., Maeda, S., Li, Z. W., Long, J. M., et al. (2005). IKK-β links inflammation to obesity-induced insulin resistance. *Nat Med*, 11(2), 191–198.

Azevedo, M., & Alla, S. (2008). Diabetes in sub-saharan Africa: kenya, mali, mozambique, Nigeria, South Africa and zambia. *Int J Diabetes Dev Ctries*, *28*(4), 101–108.

Baker, R. G., Hayden, M. S., & Ghosh, S. (2011). NF-κB, inflammation, and metabolic disease. *Cell Metab*, 13(1), 11–22.

Bakris, G. L., Fonseca, V. A., Sharma, K., & Wright, E. M. (2009). Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. *KI*, *75*(12), 1272–1277.

Bashir, M., Naem, E., Taha, F., Konje, J. C., & Abou-Samra, A. B. (2019). Outcomes of type 1 diabetes melitus in pregnancy; effect of excessive gestational weight gain and hyperglycaemia on fetal growth. *Diabetes Metab Syndr*, *13*(1), 84–88.

Bays, H., Mandarino, L., & DeFronzo, R. A. (2004). Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. *J Clin Endocr*, *89*(2), 463–478.

Bevilacqua, S., Bonadonna, R., Buzzigoli, G., Boni, C., Ciociaro, D., Maccari, F., Giorico, M. A., & Ferrannini, E. (1987). Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. *Metab. Clin. Expl*, *36*(5), 502–506.

Bintang, M. (2018). *Biokimia Teknik Penelitian Edisi 2*. Erlangga, Jakarta

Biorad. (2008). D-10, Hemoglobin A1c Program Instruction Manual. Biorad Laboratories, Inc., US

Boersma, G. J., Johansson, E., Pereira, M. J., Heurling, K., Skrtic, S., Lau, J., et al. (2018). Altered Glucose Uptake in Muscle, Visceral Adipose Tissue, and Brain Predict Whole-Body Insulin Resistance and may Contribute to the Development of Type 2 Diabetes: A Combined PET/MR Study. *Horm Metab Res*, *50*(8), 627–639.

Bratanova-Tochkova, T. K., Cheng, H., Daniel, S., Gunawardana, S., Liu, Y. J., Mulvaney-Musa, J., et al. (2002). Triggering and augmentation mechanisms, granule pools, and biphasic insulin secretion. *Diabetes*, 51 Suppl 1, S83–S90.

Brown, M. S., & Goldstein, J. L. (1997). The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. *Cell*, *89*(3), 331–340.

Brownlee, M., & Hirsch, I. B. (2006). Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. *JAMA*, *295*(14), 1707–1708.

Buettner G. R. (1993). The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. *Arch. Biochem. Biophys.*, 300(2), 535–543.

Cai, D., Yuan, M., Frantz, D. F., Melendez, P. A., Hansen, L., Lee, J., et al. (2005). Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-kappaB. *Nat Med,* 11(2), 183–190.

Catalá A. (2006). An overview of lipid peroxidation with emphasis in outer segments of photoreceptors and the chemiluminescence assay. *Int J Cell Biol*, 38(9), 1482–1495.

Centers for Disease Control and Prevention. (2021). Diabetes Tests. Available at: *https://www.cdc.gov/diabetes/basics/getting-tested.html.* Diakses pada September 2022

Cersosimo, E., & DeFronzo, R. A. (2006). Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. *Diabetes/Metab Res Rev*, *22*(6), 423–436.

Cersosimo, E., Triplitt, C., Solis-Herrera, C., Mandarino, L.J. and DeFronzo, R.A. (2018). Pathogenesis of Type 2 Diabetes Mellitus. Available at: *https://www.ncbi.nlm.nih.gov/books/NBK279115/*.

Chatterjee, S., Khunti, K., & Davies, M. J. (2017). Type 2 diabetes. *Lancet (London, England)*, *389*(10085), 2239–2251.

Chiarpotto, E., Domenicotti, C., Paola, D., Vitali, A., Nitti, M., Pronzato, M. A., et al. (1999). Regulation of rat hepatocyte protein kinase C β isoenzymes by the lipid peroxidation product 4-hydroxy-2,3-nonenal: A signaling pathway to modulate vesicular transport of glycoproteins. *Hepatology (Baltimore, Md.),* 29(5), 1565–1572.

Chia, C. W., Egan, J. M., & Ferrucci, L. (2018). Age-Related Changes in Glucose Metabolism, Hyperglycemia, and Cardiovascular Risk. *Circ. Res.*, *123*(7), 886–904.

Cusi, K., Maezono, K., Osman, A., Pendergrass, M., Patti, M. E., Pratipanawatr, T., et al. (2000). Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. *J Clin Investig, 105*(3), 311–320.

Czech M. P. (2017). Insulin action and resistance in obesity and type 2 diabetes. *Nat Med*, 23(7), 804–814.

Dalgaard, L.T. and Pedersen, O., 2001. Uncoupling proteins: functional characteristics and role in the pathogenesis of obesity and Type II diabetes. *Diabetologia*, 44(8), pp.946–965.

DeFronzo, R. A., & Ferrannini, E. (1991). Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. *Diabetes care*, *14*(3), 173–194.

DeFronzo, R. A. (2009). From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. *Diabetes*, *58*(4), 773–795.

DeFronzo, R. A., Hompesch, M., Kasichayanula, S., Liu, X., Hong, Y., Pfister, M., et al. (2013). Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. *Diabetes care*, *36*(10), 3169–3176.

DeFronzo, R.A., Ferrannini, E., Groop, L., Henry, R.R., Herman, W.H., Hols. (2015). Type 2 diabetes mellitus. *Nat Rev Dis Primers,* 1:1-23.

Departemen Kesehatan RI. (2005). *Pedoman Pemeriksaan Labortorium untuk Pemeriksaan Penyakit Diabetes Melitus*. Jakarta

Després J. P. (2012). Body fat distribution and risk of cardiovascular disease: an update. *Circulation*, *126*(10), 1301–1313.

Ding, E. L., Song, Y., Malik, V. S., & Liu, S. (2006). Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. *JAMA*, 295(11), 1288–1299.

Di Paola, R., Frittitta, L., Miscio, G., Bozzali, M., Baratta, R., Centra, M.,et al. (2002). A variation in 3' UTR of hPTP1B increases specific gene expression and associates with insulin resistance. *Am J Hum Genet*, *70*(3), 806–812.

Dodson, G., & Steiner, D. (1998). The role of assembly in insulin's biosynthesis. *Curr Opin Struct Biol*, *8*(2), 189–194.

du Toit, E. F., & Donner, D.G. (2012). Myocardial Insulin Resistance: An Overview of Its Causes, Effects, and Potential Therapy. *DOAJ*.

Ensembl Asia. (2019). The International Genome Sample Resource. Available at: *https://asia.ensembl.org/Homo_sapiens/Variation/Population?db=core;r=17:17811503-17812503;v=rs2297508;vdb=variation;vf=104619247#population_freq_AFR*. Diakses pada April 2023

Esterbauer, H., Schaur, R. J., & Zollner, H. (1991). Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. *Free Radic Biol Med*, 11(1), 81–128.

Evans, J. L., Goldfine, I. D., Maddux, B. A., & Grodsky, G. M. (2002). Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. *Endocr Rev*, *23*(5), 599–622.

Fan, X. X., Leung, E. L., Xie, Y., Liu, Z. Q., Zheng, Y. F., Yao, X. J., et al. (2018). Suppression of Lipogenesis via Reactive Oxygen Species-AMPK Signaling for Treating Malignant and Proliferative Diseases. *Antioxid Redox Sign*, 28(5), 339–357.

Felder, T. K., Oberkofler, H., Weitgasser, R., Mackevics, V., Krempler, F., Paulweber, B., et al. (2007). The SREBF-1 locus is associated with type 2 diabetes and plasma adiponectin levels in a middle-aged Austrian population. *Int J Obes (2005)*, *31*(7), 1099–1103.

Ferrannini, E. (2010). Sodium-glucose transporter-2 inhibition as an antidiabetic therapy. *Nephrol Dial Transplant*, *25*(7), 2041–2043.

Freeman J. S. (2009). Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. *Cleve Clin J Med*, *76 Suppl 5*, S12–S19.

Friedman J. M. (2009). Leptin at 14 y of age: an ongoing story. *Am J Clin Nutr*, *89*(3), 973S–979S.

Fuchsberger, C., Flannick, J., Teslovich, T. M., Mahajan, A., Agarwala, V., Gaulton, K. J., et al. (2016). The genetic architecture of type 2 diabetes. *Nature*, *536*(7614), 41–47.

Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., et al. (2020). Pathophysiology of Type 2 Diabetes Mellitus. *Int J Mol Sci*, 21(17), 6275.

Gerich, J. E., Meyer, C., Woerle, H. J., & Stumvoll, M. (2001). Renal gluconeogenesis: its importance in human glucose homeostasis. *Diabetes care*, *24*(2), 382–391.

Goldstein, D. E., Little, R. R., Lorenz, R. A., Malone, J. I., Nathan, D., Peterson, C. M., & Sacks, D. B. (2004). Tests of glycemia in diabetes. *Diabetes care*, *27*(7), 1761–1773.

Graffelman J., Moreno V. (2013). The mid p-value in exact tests for Hardy-Weinberg equilibrium. *Stat. Appl. Genet. Mol. Biol.* 12, 433–448.

Grarup, N., Stender-Petersen, K. L., Andersson, E. A., Jørgensen, T., Borch-Johnsen, K., Sandbaek, A., et al. (2008). Association of variants in the sterol regulatory element-binding factor 1 (SREBF1) gene with type 2 diabetes, glycemia, and insulin resistance: a study of 15,734 Danish subjects. *Diabetes*, *57*(4), 1136–1142.

Griffiths, B., Lewis, C. A., Bensaad, K., Ros, S., Zhang, Q., Ferber, E. C., et al. (2013). Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. *Cancer Metab*, 1(1), 3.

Guo, D., Bell, E. H., Mischel, P., & Chakravarti, A. (2014). Targeting SREBP-1-driven lipid metabolism to treat cancer. *Curr Pharm Des*, *20*(15), 2619–2626.

Hammer, M., Storey, S., Hershey, D. S., Brady, V. J., Davis, E., Mandolfo, N., et al. (2019). Hyperglycemia and Cancer: A State-of-the-Science Review. *Oncol Nurs Forum*, *46*(4), 459–472.

Harbuwono, D. S., Pramono, L. A., Yunir, E., & Subekti, I. (2018). Obesity and central obesity in Indonesia: evidence from a national health survey. *MJI*, *27*(2), 114-20.

Hayden, M. S., & Ghosh, S. (2008). Shared principles in NF-kappaB signaling. *Cell*, 132(3), 344–362.

Heit, J. A., Leibson, C. L., Ashrani, A. A., Petterson, T. M., Bailey, K. R., & Melton, L. J., 3rd (2009). Is diabetes mellitus an independent risk factor for venous thromboembolism?: a population-based case-control study. *Arterioscler Thromb Vasc Biol*, *29*(9), 1399–1405.

Himanshu, D., Ali, W., & Wamique, M. (2020). Type 2 diabetes mellitus: pathogenesis and genetic diagnosis. *J Diabetes Metab Disord*, *19*(2), 1959–1966.

Hirosumi, J., Tuncman, G., Chang, L., Görgün, C. Z., Uysal, K. T., Maeda, K. (2002). A central role for JNK in obesity and insulin resistance. *Nature*, *420*(6913), 333–336.

Hirvonen, J., Virtanen, K. A., Nummenmaa, L., Hannukainen, J. C., Honka, M. J., Bucci, M., et al. (2011). Effects of insulin on brain glucose metabolism in impaired glucose tolerance. *Diabetes*, *60*(2), 443–447.

Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002). SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. *J Clin Investig*, *109*(9), 1125–1131.

Hotamisligil, G. S., & Erbay, E. (2008). Nutrient sensing and inflammation in metabolic diseases. Nature reviews. *Immunology*, 8(12), 923–934.

Huang, S., & Czech, M. P. (2007). The GLUT4 glucose transporter. *Cell Metab*, *5*(4), 237–252.

Ide, T., Shimano, H., Yahagi, N., Matsuzaka, T., Nakakuki, M., Yamamoto, T., Nakagawa, Y., Takahashi, A., Suzuki, H., Sone, H., Toyoshima, H., Fukamizu, A., & Yamada, N. (2004). SREBPs suppress IRS-2-mediated insulin signalling in the liver. *Nat. Cell Biol*, *6*(4), 351–357.

Insel, R. A., Dunne, J. L., Atkinson, M. A., Chiang, J. L., Dabelea, D., Gottlieb, P. A., et al. (2015). Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. *Diabetes care*, *38*(10), 1964–1974.

International Diabetes Federation. (2022). Diabetes around the world in 2021. Available at: *https://diabetesatlas.org/*. Diakses pada Agustus 2022

Jeon, T. I., & Osborne, T. F. (2012). SREBPs: metabolic integrators in physiology and metabolism. *Trends Endocrinol Metab: TEM*, *23*(2), 65–72.

Jin, X., Zeng, F., Zhang, N., Huang, T., Meng, Q., & Liu, Y. (2012). Association of sterol regulatory element-binding transcription factor gene polymorphisms with ischaemic stroke. *Int J Med Res*, *40*(1), 157–166.

Johnson, E. L dan Robert, S. (1991). *Dasar Kromatografi Cair*. Institut Teknologi Bandung, Bandung.

Jongberg, S., Carlsen, C. U., & Skibsted, L. H. (2009). Peptides as antioxidants and carbonyl quenchers in biological model systems. *Free Radic Res*, 43(10), 932–942.

Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006). Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature*, *444*(7121), 840–846.

Kemenkes RI, 2016. Rencana aksi nasional kesehatan lanjut usia tahun 2016-2019. *http://hukor.kemkes.go.id/uploads/produk_hukum/PMK_No._25_ttg_Rencana_Aksi_Nasional_Kesehatan_Lanjut_Usia_Tahun_2016-2019.pdf*. Diakses tanggal 9 April 2023.

Kewalramani, G., Bilan, P. J., & Klip, A. (2010). Muscle insulin resistance: assault by lipids, cytokines and local macrophages. *Curr Opin Clin Nutr Metab Care*, *13*(4), 382–390.

Khan, H. A., Sobki, S. H., & Khan, S. A. (2007). Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia. *Clin. Exp. Med., 7*(1), 24–29.

Kim, J. K., Kim, Y. J., Fillmore, J. J., Chen, Y., Moore, I., Lee, J., et al. (2001). Prevention of fat-induced insulin resistance by salicylate. *J Clin Investig*, 108(3), 437–446.

Kim, H. J., Higashimori, T., Park, S. Y., Choi, H., Dong, J., Kim, Y. J. (2004). Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. *Diabetes*, *53*(4), 1060–1067.

King, P., Peacock, I., & Donnelly, R. (1999). The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. *Br. J. Clin. Pharmacol*, *48*(5), 643–648.

Kopp, E., & Ghosh, S. (1994). Inhibition of NF-kappa B by sodium salicylate and aspirin. *N Y Sci J*, 265(5174), 956–959.

Kraegen, E. W., Sowden, J. A., Halstead, M. B., Clark, P. W., Rodnick, K. J., Chisholm, D. J. (1993). Glucose transporters and in vivo glucose uptake in skeletal and cardiac muscle: fasting, insulin stimulation and immunoisolation studies of GLUT1 and GLUT4. *Biochem J*, *295 (Pt 1)*, 287–293.

Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., et al. (2018). Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. *Lancet (London, England)*, *391*(10120), 541–551.

Lebrun, P., & Van Obberghen, E. (2008). SOCS proteins causing trouble in insulin action. *Acta Physiol*, *192*(1), 29–36.

Lee, J. H., Jeon, Y. G., Lee, K. H., Lee, H. W., Park, J., Jang, H., et al. (2017). RNF20 Suppresses Tumorigenesis by Inhibiting the SREBP1c-PTTG1 Axis in Kidney Cancer. *Mol Cell Biol*, 37(22), e00265-17.

Lehninger, A. L., & Nelson, D. L. (2010). *Lehninger principles of biochemistry* (4th ed.). Academic Internet Publishers.

Li, L., Yun, J. H., Ryoo, J. E., Lee, K. J., Choi, B. C., & Baek, K. H. (2015). 54G/C polymorphism of SREBF-1 gene is associated with polycystic ovary syndrome. *Eur J Obstet Gynecol Reprod Biol*, *188*, 95–99.

Liang, G., Yang, J., Horton, J. D., Hammer, R. E., Goldstein, J. L., & Brown, M. S. (2002). Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. *J Biol Chem*, *277*(11), 9520–9528.

Liu, J. X., Liu, J., Li, P. Q., Xie, X. D., Guo, Q., Tian, L. M., et al. (2008). Association of sterol regulatory element-binding protein-1c gene polymorphism with type 2 diabetes melitus, insulin resistance and blood lipid levels in Chinese population. *J Diabetes Res*, *82*(1), 42–47.

Liu, J. X., Liu, J., Guo, Q., & Liu, J. (2012). Association of sterol regulatory element binding protein-1c genetic polymorphisms rs2297508 and rs11868035 with type 2 diabetes melitus in Gansu Han and Dongxiang population. *Chin Med J*, *29*(3), 328–333.

Lyssenko, V., Jonsson, A., Almgren, P., Pulizzi, N., Isomaa, B., Tuomi, T, et al. (2008). Clinical risk factors, DNA variants, and the development of type 2 diabetes. *N Engl J Med*, *359*(21), 2220–2232.

Ma, X., Zhao, T., Yan, H., Guo, K., Liu, Z., Wei, L., et al. (2021). Fatostatin reverses progesterone resistance by inhibiting the SREBP1-NF-κB pathway in endometrial carcinoma. *Cell Death Dis*, 12(6), 544.

Mahmud, F. R., Sudirman, Afni, N. (2018). Faktor-Faktor yang Berhubungan dengan Penyakit Diabetes Melitus di Ruang Poli Interna RSUD Mokopido Kabupaten Toli-Toli. *J-Kesmas,* 1(1), 168-175

Majithia, A. R., & Florez, J. C. (2009). Clinical translation of genetic predictors for type 2 diabetes. *Curr Opin Endocrinol Diabetes Obes*, *16*(2), 100–106.

Makris, K., & Spanou, L. (2011). Is there a relationship between mean blood glucose and glycated hemoglobin?. *JDST*, *5*(6), 1572–1583.

Malaisse WJ. (1997). *Insulin biosynthesis and secretion in vitro*. In: Alberti KGMM, Zimmet P, Defronzo RA & Keen H (Hon) editors. International Textbook of Diabetes Melitus (2nd ed) John Wiley & Sons. New York. p. 315–36

McCarthy M. I. (2010). Genomics, type 2 diabetes, and obesity. *N Engl J Med, 363*(24), 2339–2350.

Meyer, C., Stumvoll, M., Nadkarni, V., Dostou, J., Mitrakou, A., & Gerich, J. (1998). Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. *J Clin Investig*, *102*(3), 619–624.

Mignone, F., & Pesole, G. (2018). mRNA Untranslated Regions (UTRs). *ELS*, 1–6. Available at: https://doi.org/10.1002/9780470015902.a0005009.pub3

Monnier, L., & Colette, C. (2008). Glycemic variability: should we and can we prevent it?. *Diabetes care*, *31 Suppl 2*, S150–S154.

Moon, Y.A. (2017). The SCAP/SREBP Pathway: A Mediator of Hepatic Steatosis. *Endocrinol Metab, 32*, 6 - 10.

Murni, I.K., Sulistyoningrum, D.C., Susilowati, R., Julia, M. and Dickinson, K.M. (2022). The association between dietary intake and cardiometabolic risk factors among obese adolescents in Indonesia. *BMC Pediatr*, 22(1).

Nagata, R., Nishio, Y., Sekine, O., Nagai, Y., Maeno, Y., Ugi, S., Maegawa, H., & Kashiwagi, A. (2004). Single nucleotide polymorphism (-468 Gly to A) at the promoter region of SREBP-1c associates with genetic defect of fructose-induced hepatic lipogenesis [corrected]. *JBC*, *279*(28), 29031–29042.

Nauck, M. A., Baller, B., & Meier, J. J. (2004). Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. *Diabetes*, 53 Suppl 3, S190–S196.

Ndisang, J. F., Rastogi, S., & Vannacci, A. (2014). Insulin resistance, type 1 and type 2 diabetes, and related complications: current status and future perspective. *J Diabetes Res*, *2014*, 276475.

Nigam, S., & Schewe, T. (2000). Phospholipase A(2)s and lipid peroxidation. *Biochim Biophys Acta Bioenerg*, 1488(1-2), 167–181.

Nohturfft, A., Brown, M. S., & Goldstein, J. L. (1998). Topology of SREBP Cleavage-activating Protein, a Polytopic Membrane Protein with a Sterol-sensing Domain. *J Biol Chem*, *273*(27), 17243–17250.

Ozougwu, J.C., Obimba, K.C., Belonwu, C.D. and Unakalamba., C.B. (2013). the pathogenesis and pathophysiology of type 1 and type 2 diabetes melitus. *J Physio Patho, 4(4),* 26-36

Pagotto U. (2009). Where does insulin resistance start? The brain. *Diabetes care*, 32 Suppl *2*(Suppl 2), S174–S177.

Parola, M., Bellomo, G., Robino, G., Barrera, G., & Dianzani, M. U. (1999). 4-Hydroxynonenal as a biological signal: molecular basis and pathophysiological implications. *Antioxid Redox Sign*, 1(3), 255–284.

Pearson, T., Wattis, J. A., King, J. R., MacDonald, I. A., & Mazzatti, D. J. (2016). The Effects of Insulin Resistance on Individual Tissues: An Application of a Mathematical Model of Metabolism in Humans. *Bull Math Biol*, 78(6), 1189–1217.

Peng, X. E., Chen, F. L., Liu, W., Hu, Z., & Lin, X. (2016). Lack of association between SREBP-1c gene polymorphisms and risk of non-alcoholic fatty liver disease in a Chinese Han population. *Sci Rep, 6*, 32110.

Petersen, K. F., & Shulman, G. I. (2006). Etiology of insulin resistance. *Am J Med*, 119(5 Suppl 1), S10–S16.

Petersen, M. C., & Shulman, G. I. (2018). Mechanisms of Insulin Action and Insulin Resistance. *Physiol Rev*, *98*(4), 2133–2223.

Petrie, J. R., Guzik, T. J., & Touyz, R. M. (2018). Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. *CJC*, *34*(5), 575–584.

Pickering, B. M., & Willis, A. E. (2005). The implications of structured 5' untranslated regions on translation and disease. *Semin Cell Dev Biol*, *16*(1), 39–47.

Qin, S., & Rodrigues, G. A. (2010). Differential roles of AMPKα1 and AMPKα2 in regulating 4-HNE-induced RPE cell death and permeability. *Exp Eye Res*, 91(6), 818–824.

Reaven G. (2003). Insulin resistance, hypertension, and coronary heart disease. *J. Clin. Hypertens. (Greenwich, Conn.)*, *5*(4), 269–274.

Riset Kesehatan Dasar (Riskesdas). (2018). Hasil Utama Riskesdas Tentang Prevalensi Diabetes Melitus di Indonesia 2018. Available at: *https://dinkes.kalbarprov.go.id/wp-content/uploads/2019/03/Laporan-Riskesdas-2018-Nasional.pdf*. Diakses pada Juli 2022

Robinet, P., Védie, B., Chironi, G., Gariépy, J., Simon, A., Moatti, N., et al. (2003). Characterization of polymorphic structure of SREBP-2 gene: role in atherosclerosis. *Atherosclerosis*, *168*(2), 381–387.

Roden, M., & Shulman, G. I. (2019). The integrative biology of type 2 diabetes. *Nature*, *576*(7785), 51–60.

Roth, J. D., Maier, H., Chen, S., & Roland, B. L. (2009). Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications. *Arch Neurol*, *66*(3), 306–310.

Rubbo, H., Parthasarathy, S., Barnes, S., Kirk, M., Kalyanaraman, B., & Freeman, B. A. (1995). Nitric oxide inhibition of lipoxygenase-dependent liposome and low-density lipoprotein oxidation: termination of radical chain propagation reactions and formation of nitrogen-containing oxidized lipid derivatives. *Arch Biochem*, 324(1), 15–25.

Sachdev, H. P., Osmond, C., Fall, C. H., Lakshmy, R., Ramji, S., Dey Biswas, S. K., et al. (2009). Predicting adult metabolic syndrome from childhood body mass index: follow-up of the New Delhi birth cohort. *Arch Dis Child Lond*, *94*(10), 768–774.

Sastroasmoro, S., Ismael, S. 1995. *Dasar-dasar metodologi penelitian klinis* Edisi1. Binarupa Aksara, Jakarta.

Sato R. (2010). Sterol metabolism and SREBP activation. *Arch Biochem*, *501*(2), 177–181.

Satoh T. (2014). Molecular mechanisms for the regulation of insulin-stimulated glucose uptake by small guanosine triphosphatases in skeletal muscle and adipocytes. *Int J Mol Sci*, 15(10), 18677–18692.

Schwartz, S. S., Epstein, S., Corkey, B. E., Grant, S. F., Gavin, J. R. & Aguilar, R. B. (2016). The Time Is Right for a New Classification System for Diabetes:

Rationale and Implications of the β-Cell-Centric Classification Schema. *Diabetes care*, *39*(2), 179–186.

Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., & Brancati, F. L. (2010). Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. *NEJM.*, *362*(9), 800–811.

Sewter, C., Berger, D., Considine, R. V., Medina, G., Rochford, J., Ciaraldi, T., et al. (2002). Human obesity and type 2 diabetes are associated with alterations in SREBP-1 isoform expression that are reproduced ex vivo by tumor necrosis factor-alpha. *Diabetes*, *51*(4), 1035–1041.

Shah, P., Vella, A., Basu, A., Basu, R., Schwenk, W. F., & Rizza, R. A. (2000). Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. *J Clin Endocr*, *85*(11), 4053–4059.

Shapiro, R., McManus, M. J., Zalut, C., & Bunn, H. F. (1980). Sites of nonenzymatic glycosylation of human hemoglobin A. *JBC*, *255*(7), 3120–3127.

Solis-Herrera C, Triplitt C, Reasner C, et al. (2018).*Classification of Diabetes Melitus*. In: Feingold KR, Anawalt B, Boyce A, et al., editors. MDText.com, Inc., South Dartmouth (MA)

Solis-Herrera, C., Triplitt, C., Reasner, C., DeFronzo, R.A. and Cersosimo, E. (2000). Classification of Diabetes Mellitus. Available at: *https://www.ncbi.nlm.nih.gov/books/NBK279119/?report=classic*. Diakses pada September 2022.

Steen, V. M., Skrede, S., Polushina, T., López, M., Andreassen, O. A., Fernø, J., et al. (2017). Genetic evidence for a role of the SREBP transcription system and lipid biosynthesis in schizophrenia and antipsychotic treatment. *Eur Neuropsychopharmacol*, *27*(6), 589–598.

Stratton, I. M., Adler, A. I., Neil, H. A., Matthews, D. R., Manley, S. E. & Cull, C. A. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ (Clinical research ed.)*, *321*(7258), 405–412.

Stumvoll, M., Chintalapudi, U., Perriello, G., Welle, S., Gutierrez, O., & Gerich, J. (1995). Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine. *J Clin Investig*, *96*(5), 2528–2533.

Teufel, F., Seiglie, J. A., Geldsetzer, P., Theilmann, M., Marcus, M. E., Ebert, C., et al. (2021). Body-mass index and diabetes risk in 57 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data in 685 616 adults. *Lancet (London, England)*, *398*(10296), 238–248.

The World Bank. (2021). Diabetes prevalence (% of population ages 20 to 79. Available at: *https://data.worldbank.org/indicator/SH.STA.DIAB.ZS*. Diakses pada Agustus 2022

Timper, K., & Brüning, J. C. (2017). Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity. *Dis Model Mech*, *10*(6), 679–689.

Uchida K. (1999). Current status of acrolein as a lipid peroxidation product. *Trends Cardiovasc Med*, 9(5), 109–113.

Unger, R. H., & Zhou, Y. (2001). Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. *Diabetes*, *50*(Supplement 1), S118–S121.

Vague, P., Juhan-Vague, I., Aillaud, M. F., Badier, C., Viard, R., Alessi, M. C., et al. (1986). Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. *Metab. Clin. Exp*, *35*(3), 250–253.

Vargas-Alarcon, G., Gonzalez-Pacheco, H., Perez-Mendez, O., Posadas-Sanchez, R., Cardoso-Saldaña, G., Ramirez-Bello, J., et al. (2019). SREBF1c and SREBF2 gene polymorphisms are associated with acute coronary syndrome and blood lipid levels in Mexican population. *PloS one*, 14(9), e0222017.

Villegas-Valverde, C. C., Kokuina, E., & Breff-Fonseca, M. C. (2018). Strengthening National Health Priorities for Diabetes Prevention and Management. *MED Rev*, *20*(4), 5.

Vincent, M. A., Clerk, L. H., Lindner, J. R., Klibanov, A. L., Clark, M. G., Rattigan, S., et al. (2004). Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. *Diabetes*, *53*(6), 1418–1423.

Vlassara, H., & Uribarri, J. (2014). Advanced glycation end products (AGE) and diabetes: cause, effect, or both?. *Curr. Diabetes Rev. 14*(1), 453

Wang, Z., Emmerich, A., Pillon, N. J., Moore, T., Hemerich, D., & Cornelis, M. C. (2022). Genome-wide association analyses of physical activity and sedentary behavior provide insights into underlying mechanisms and roles in disease prevention. *Nat Genet*, *54*(1332–1344), 1–13.

Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., & Ferrante, A. W., Jr (2003). Obesity is associated with macrophage accumulation in adipose tissue. *J Clin Investig*, *112*(12), 1796–1808.

Wentholt, I. M., Kulik, W., Michels, R. P., Hoekstra, J. B., & DeVries, J. H. (2008). Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. *Diabetologia*, *51*(1), 183–190.

Wilcox G. (2005). Insulin and insulin resistance. *Clin Biochem Rev*, *26*(2), 19–39.

Wondmkun Y. T. (2020). Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications. *Diabetes Metab. Syndr. Obes.: Targets Therapy*, *13*, 3611–3616.

Yadav, U. C., & Ramana, K. V. (2013). Regulation of NF-κB-induced inflammatory signaling by lipid peroxidation-derived aldehydes. *Oxid Med Cell*, 2013, 690545.

Yari, Z., Behrouz, V., Zand, H., & Pourvali, K. (2020). New Insight into Diabetes Management: From Glycemic Index to Dietary Insulin Index. *Curr Diabetes Rev*, *16*(4), 293–300.

Yi, M., Li, J., Chen, S., Cai, J., Ban, Y., Peng, Q., et al. (2018). Emerging role of lipid metabolism alterations in Cancer stem cells. *J Exp Clin Cancer Res*, 37(1), 118.

Yin, M. J., Yamamoto, Y., & Gaynor, R. B. (1998). The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-β. *Nature*, 396(6706), 77–80.

Yu, C., Chen, Y., Cline, G. W., Zhang, D., Zong, H., Wang, Y. (2002). Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. *J Biol Chem*, *277*(52), 50230–50236.

Yuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z. W., Karin, M., et al. (2001). Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. *N Y Sci J* 293(5535), 1673–1677.

Zhang, X., Gregg, E. W., Williamson, D. F., Barker, L. E., Thomas, W., Bullard, K. M., et al. (2010). A1C level and future risk of diabetes: a systematic review. *Diabetes care*, *33*(7), 1665–1673.

Zhang, Z., Gong, R. R., Du, J., Xiao, L. Y., Duan, W., Zhou, X. D., et al. (2011). Associations of the SREBP-1c gene polymorphism with gender-specific changes in serum lipids induced by a high-carbohydrate diet in healthy Chinese youth. *Appl Physiol Nutr Metab*, *36*(2), 226–232.